Who has been buying HLB Therapeutics stock?

2 distinct insiders have filed 9 disclosed insider purchases in HLB Therapeutics (115450), most recently on 2026-06-29. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does HLB Therapeutics have?

HLB Therapeutics has 9 buy-side and 0 sell-side disclosures on record, covering ₩3.6B ($2.5M) in total reported value, spanning 2024-03-19 to 2026-06-29.

Where does StockDrifts get HLB Therapeutics insider data?

From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

HLB Therapeutics 115450

Company

HLB테라퓨틱스HLB Therapeutics

Insiders

Buys

Total Value

₩3.6B ($2.5M)

Avg Return

-59.56%

Last Filing

2026-06-29

HLB Therapeutics (115450) has 9 disclosed insider purchases and 0 disclosed disposals on record, filed by 2 distinct insiders. Together those filings cover ₩3.6B ($2.5M) in reported transaction value. The earliest filing StockDrifts holds for HLB Therapeutics is dated 2024-03-19; the most recent is 2026-06-29. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is -59.56%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-07-22	BUY	Market Buy	진양곤 Jinyanggon	Internal director	34.1K	₩1,731	-4.3%	₩58M ($40K)
2026-06-29	BUY	Market Buy	진양곤 Jinyanggon	Internal director	20.0K	-	-	-
2026-06-10	BUY	Market Buy	진양곤 Jinyanggon	Internal director	33.0K	-	-	-
2026-06-09	BUY	Market Buy	진양곤 Jinyanggon	Internal director	30.0K	-	-	-
2026-06-08	BUY	Market Buy	진양곤 Jinyanggon	Internal director	4.3K	-	-	-
2026-06-04	BUY	Market Buy	진양곤 Jinyanggon	Internal director	25.0K	-	-	-
2026-06-02	BUY	Market Buy	진양곤 Jinyanggon	Internal director	11.0K	-	-	-
2026-03-17	BUY	Market Buy	진양곤 Jinyanggon	Internal director	19.5K	-	-	-
2026-03-13	BUY	무상신주취득	HLB	-	81.4K	-	-	-
2026-03-13	BUY	무상신주취득	HLB	-	334.8K	-	-	-
2026-03-13	BUY	무상신주취득	진양곤 Jinyanggon	Internal director	11.2K	-	-	-
2026-03-06	BUY	Market Buy	진양곤 Jinyanggon	Internal director	33.0K	-	-	-
2025-08-28	BUY	행사가액조정	HLB	-	39.4K	₩3,100	-7.4%	₩122M ($85K)
2025-08-21	BUY	행사가액조정	HLB	-	138.6K	₩3,230	-11.2%	₩448M ($311K)
2025-05-28	BUY	행사가액조정	HLB	-	171.3K	₩8,470	-66.1%	₩1.5B ($1.0M)
2025-05-21	BUY	행사가액조정	HLB	-	143.0K	₩7,210	-60.2%	₩1.0B ($716K)
2025-02-28	BUY	CB인수	HLB	-	491.7K	₩10,350	-72.3%	₩5.1B ($3.5M)
2025-01-15	BUY	무상신주취득	HLB	-	318.9K	₩11,450	-74.9%	₩3.7B ($2.5M)
2025-01-15	BUY	행사가액조정	HLB	-	31.1K	₩11,450	-74.9%	₩356M ($247K)
2024-11-21	BUY	CB인수	HLB	-	626.0K	₩10,012	-71.3%	₩6.3B ($4.4M)
2024-05-22	BUY	Market Buy	HLB	-	512.0K	₩7,097	-59.6%	₩3.6B ($2.5M)
2024-04-02	BUY	제3자배정유상증자	HLB	-	1.0M	₩13,022	-78.0%	₩13.2B ($9.1M)
2024-03-26	BUY	주식배당	안기홍 Kihong Ahn	CEO	1.9K	₩13,908	-79.4%	₩26M ($18K)
2024-03-26	BUY	주식배당	HLB	-	141.4K	₩13,908	-79.4%	₩2.0B ($1.4M)
2024-03-19	BUY	시간외매매	HLB	-	673.0K	₩9,231	-68.9%	₩6.2B ($4.3M)

Frequently asked questions

Who has been buying HLB Therapeutics stock?: 2 distinct insiders have filed 9 disclosed insider purchases in HLB Therapeutics (115450), most recently on 2026-06-29. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does HLB Therapeutics have?: HLB Therapeutics has 9 buy-side and 0 sell-side disclosures on record, covering ₩3.6B ($2.5M) in total reported value, spanning 2024-03-19 to 2026-06-29.
Where does StockDrifts get HLB Therapeutics insider data?: From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for HLB Therapeutics. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.